glp-1 producers Glucagon-like peptide-1 Use of GLP - 1

They minimize systemic inflammation by many mechanisms: direct suppression of pro-inflammatory cytokine synthesis (TNF-, IL-6, IL-1), augmentation of anti-inflammatory mediators (IL-10, adiponectin), and alteration of immune cell morphologies

Potential sleep disturbances and bone pain in some individuals

Endogenous incretin levels and risk of first incident cancer: a prospective cohort study

This information is educational only and is not a promise of results

However, there is not yet any direct evidence that someone's body composition would be worse after stopping weight-loss drugs than before they started

it has been hypothesised to complement GLP-1 activity, though evidence in humans remains limited